[1]邵毅,葛倩敏,陈序.糖尿病黄斑水肿患者行醋酸氟轻松治疗规范：2023年专家共识解读[J].眼科新进展,2023,43(10):757-760.[doi:10.13389/j.cnki.rao.2023.0152]
　SHAO Yi,GE Qianmin,CHEN Xu.Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023[J].Recent Advances in Ophthalmology,2023,43(10):757-760.[doi:10.13389/j.cnki.rao.2023.0152]
点击复制

糖尿病黄斑水肿患者行醋酸氟轻松治疗规范：2023年专家共识解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年10期
页码:
757-760
栏目:
述评
出版日期:
2023-10-05

文章信息/Info

Title:
Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023
作者:
邵毅; 葛倩敏; 陈序
200031　上海市,复旦大学附属眼耳鼻喉科医院(邵毅);330006　江西省南昌市，南昌大学第一附属医院眼科(葛倩敏)；6200MS　荷兰林堡省马斯特里赫特市，马斯特里赫特大学眼科中心(陈序)
Author(s):
SHAO Yi1; GE Qianmin2; CHEN Xu3
1.Eye & ENT Hospital of Fudan University,Shanghai 200031,China
2.Department of Ophthalmology，the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
3.Ophthalmology Centre of Maastricht University,Maastricht 6200MS,Limburg Province,Netherlands
关键词:
醋酸氟轻松; 糖尿病视网膜病变; 糖尿病黄斑水肿; 治疗; 共识
Keywords:
fluocinolone acetonide;  diabetic retinopathy;  diabetic macular edema;  treatment;  consensus
分类号:
R777.31
DOI:
10.13389/j.cnki.rao.2023.0152
文献标志码:
A
摘要:
为了更好地了解视网膜病专家对于炎症在糖尿病视网膜病变（DR）和糖尿病黄斑水肿（DME）中所起作用的一致程度，以及使用0.19 mg醋酸氟轻松（FAc）玻璃体内注射治疗DME的效果认同情况，起草了一份共识调查报告，共有56名美国视网膜病专家完成了整个共识调查。医生高度同意炎症在DR/DME的病理生理学、注射负荷和患者依从性、FAc玻璃体内注射的有效性和安全性方面的作用。然而，对于FAc植入剂对DR进展的影响、FAc作为DME的基线治疗以及类固醇刺激降低FAc使用后眼压风险的有效性，尚未达成共识。本文就该专家共识进行解读，为FAc玻璃体内注射治疗DR/DME方案的进一步研究和应用提供参考。
Abstract:
To better understand the consistency in the role of inflammation in diabetic retinopathy (DR) and diabetic macular edema (DME) and the efficacy of injecting 0.19 mg fluocinolone acetonide (FAc) intravitreally to treat DME, a consensus survey report was drafted by 56 retinal disease experts from the United States. Doctors highly agreed on the role of inflammation in DR/DME pathophysiology, injection loading and patient compliance, as well as the efficacy and safety of FAc injections. However, no consensus has been established on the effect of FAc implants on DR progression, the efficacy of FAc as a baseline treatment for DME, and the effectiveness of steroid stimulation to reduce the risk of intraocular pressure after FAc use. This paper interprets the expert consensus, providing references for further research and application of FAc injections for DR/DME treatment.

参考文献/References:

［1］　SACCONI R,GIUFFR C,CORBELLI E,BORRELLI E,QUERQUES G,BANDELLO F.Emerging therapies in the management of macular edema:a review［J］.F1000Res,2019,8:F1000 Faculty Rev-1413.
［2］　TEO Z L,THAM Y C,YU M,CHEE M L,RIM T H,CHEUNG N,et al.Global prevalence of diabetic retinopathy and projection of burden through 2045:systematic review and meta-analysis［J］.Ophthalmology,2021,128(11):1580-1591.
［3］　HUTTON D W,GLASSMAN A R,STEIN J D,BRESSLER N M,SUN J K.Costs of managing diabetic macular edema with good visual acuity with aflibercept,laser,or observation:DRCR retina network protocol V［J］.Am J Ophthalmol,2021,230:297-302.
［4］　RBSAM A,PARIKH S,FORT P E.Role of inflammation in diabetic retinopathy［J］.Int J Mol Sci,2018,19(4):942.
［5］　ROMERO-AROCA P,BAGET-BERNALDIZ M,PAREJA-RIOS A,LOPEZ-GALVEZ M,NAVARRO-GIL R,VERGES R.Diabetic macular edema pathophysiology:vasogenic versus inflammatory［J］.J Diabetes Res,2016,2016:2156273.
［6］　SOHN E H,VAN DIJK H W,JIAO C,KOK P H,JEONG W,DEMIRKAYA N,et al.Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus［J］.Proc Natl Acad Sci U S A,2016,113(19):E2655-E2664.
［7］　JONSSON K B,FRYDKJAER-OLSEN U,GRAUSLUND J.Vascular changes and neurodegeneration in the early stages of diabetic retinopathy:which comes first?［J］.Ophthalmic Res,2016,56(1):1-9.
［8］　LYNCH S K,ABRMOFF M D.Diabetic retinopathy is a neurodegenerative disorder［J］.Vis Res,2017,139:101-107.
［9］　COUGHLIN B A,FEENSTRA D J,MOHR S.Müller cells and diabetic retinopathy［J］.Vis Res,2017,139:93-100.
［10］　JANSEN M E,HARIPRASAD S M,SINGER M A.Treatments for diabetic macular edema:past,present,and future［J］.Ophthalmic Surg Lasers Imaging Retina,2016,47(9):794-800.
［11］　HARIPRASAD S.Current approaches to the management of diabetic macular edema［J］.Am J Manag Care,2016,22(10 Suppl):s292-s299.
［12］　KUBOTA T,MORITA H,TOU N,NITTA N,TAWARA A,SATOH H,et al.Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab［J］.Retina,2010,30(3):468-472.
［13］　BRESSLER N M,BEAULIEU W T,GLASSMAN A R,BLINDER K J,BRESSLER S B,JAMPOL L M,et al.Persistent macular thickening following intravitreous aflibercept,bevacizumab,or ranibizumab for central-involved diabetic macular edema with vision impairment:a secondary analysis of a randomized clinical trial［J］.JAMA Ophthalmol,2018,136(3):257-269.
［14］　STARR M R,SALABATI M,MAHMOUDZADEH R,PATEL L G,AMMAR M J,HSU J,et al.Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting［J］.Am J Ophthalmol,2021,232:90-97.
［15］　CHAKRAVARTHY U,HAVILIO M,SYNTOSI A,PILLAI N,WILKES E,BENYAMINI G,et al.Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD［J］.Eye,2021,35(11):2983-2990.
［16］　CHAWAN-SAAD J,WU M,WU A,WU L.Corticosteroids for diabetic macular edema［J］.Taiwan J Ophthalmol,2019,9(4):233-242.
［17］　IXCAMEY M,PALMA C.Diabetic macular edema［J］.Dis Mon,2021,67(5):101138.
［18］　WELLS J A,GLASSMAN A R,AYALA A R,JAMPOL L M,BRESSLER N M,BRESSLER S B,et al.Aflibercept,bevacizumab,or ranibizumab for diabetic macular edema［J］.Ophthalmology,2016,123(6):1351-1359.
［19］　WEISS M,SIM D A,HEROLD T,SCHUMANN R G,LIEGL R,KERN C,et al.Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice［J］.Retina,2018,38(12):2293-2300.
［20］　SINGER M A,SHETH V,MANSOUR S E,COUGHLIN B,GONZALEZ V H.Three-year safety and efficacy of the 0.19 mg fluocinolone acetonide intravitreal implant for diabetic macular edema:the PALADIN study［J］.Ophthalmology,2022,129(6):605-613.
［21］　CAMPOCHIARO P A,NGUYEN Q D,HAFIZ G,BLOOM S,BROWN D M,BUSQUETS M,et al.Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants［J］.Ophthalmology,2013,120(3):583-587.
［22］　HOLDEN S E,HABIB M,CURRIE C J.Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema［J］.Curr Med Res Opin,2020,36(6):959-965.
［23］　EATON A,KOH S S,JIMENEZ J,RIEMANN C D.The USER study:a chart review of patients receiving a 0.2 μg/day fluocinolone acetonide implant for diabetic macular edema［J］.Ophthalmol Ther,2019,8(1):51-62.
［24］　RIEMANN C,EATON A,CUTINO A.Reduction in retinal thickness fluctuations after treatment with fluocinolone acetonide implant for DME:a post-hoc analysis of the USER study［J］.Osli Retina,2020,51(5):298-306.
［25］　PARRISH R,CAMPOCHIARO P,PEARSON P A,GREEN K,TRAVERSO C.Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials［J］.Osli Retina,2016,47(5):426-435.
［26］　SHARMA S.Interleukin-6 trans-signaling:a pathway with therapeutic potential for diabetic retinopathy［J］.Front Physiol,2021,12:689429.
［27］　杨凯转,乔玉好,闫淑.玻璃体内注射抗VEGF药物对糖尿病黄斑水肿患者疗效的影响因素分析［J］.眼科新进展,2023,43(4):298-302,307.
YANG K Z,QIAO Y H,YAN S.Influencing factors for therapeutic effect of intravitreal injection of anti-vascular endothelial growth factor agents in patients with diabetic macular edema［J］.Rec Adv Ophthalmol,2023,43(4):298-302,307.
［28］　邵毅,石文卿,肖昂.解读“亚洲人群糖尿病黄斑水肿管理专家小组共识”［J］.眼科新进展,2021,41(9):801-805.
SHAO Y,SHI W Q,XIAO A.Diabetic macular edema management in Asian populations:expert panel consensus guidelines［J］.Rec Adv Ophthalmol,2021,41(9):801-805.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[6]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[7]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[8]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[9]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[10]李小璐 马雅玲.糖尿病视网膜病变大鼠视网膜VEGF和PEDF的动态表达[J].眼科新进展,2013,33(9):000.

备注/Memo

备注/Memo:
国家自然科学基金项目（编号:82160195）；中央引导地方科技发展资金项目（编号:20211ZDG02003）
更新日期/Last Update: 2023-10-05